Substituted biaryl quinolin-4-ylamine analogues of Formula I are provided.
Such compounds are ligands that may be used to modulate specific
receptor activity in vivo or in vitro, and are particularly useful in the
treatment of conditions associated with pathological receptor activation
in humans, domesticated companion animals and livestock animals.
Pharmaceutical compositions and methods for using such compounds to treat
such disorders are provided, as are methods for using such ligands for
receptor localization studies.